STOCK TITAN

Ardelyx, Inc. - $ARDX STOCK NEWS

Welcome to our dedicated page for Ardelyx news (Ticker: $ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ardelyx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ardelyx's position in the market.

Rhea-AI Summary
Ardelyx shares encouraging data on IBSRELA at GHAPP conference, demonstrating safety and efficacy of the treatment. Patients reported reduction in abdominal symptom scores and higher treatment satisfaction. Pooled analysis shows higher proportion of patients with durable complete spontaneous bowel movement response. No significant negative impacts on stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
none
-
Rhea-AI Summary
Ardelyx CEO to present at H.C. Wainwright Conference on Sept. 11 at 12:00 p.m. ET in NYC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
conferences
-
Rhea-AI Summary
Ardelyx, Inc. granted new options and RSUs to non-executive employees as inducements for employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
none
Rhea-AI Summary
Ardelyx reports Q2 net sales revenue of $18.3 million for IBSRELA and expects full-year revenue to be between $72 and $77 million. XPHOZAH launch expected in Q4 pending FDA approval. Company ends Q2 with $127.6 million in cash and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.22%
Tags
none
-
Rhea-AI Summary
Ardelyx, Inc. will hold a conference call on August 2, 2023, at 8:00 a.m. Eastern Time to discuss second quarter financial results and provide a business update. The call can be accessed by dialing (844) 481-2838 (domestic) or (412) 317-1858 (international). The live audio of the call will be webcasted and available for replay on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences earnings
Rhea-AI Summary
Ardelyx, Inc. (Nasdaq: ARDX) to present at H.C. Wainwright 2nd Annual Kidney Conference. Mike Raab, president and CEO, to speak on July 25, 2023, at 2:00 P.M. Eastern Time. Webcast available on Ardelyx website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
conferences
Ardelyx, Inc.

Nasdaq:ARDX

ARDX Rankings

ARDX Stock Data

2.04B
226.69M
1.95%
60.33%
15.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FREMONT

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.